Sign up to save your podcasts
Or
Share ME/CFS and long COVID; negative outcomes for ALS drug; donanemab
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
ME/CFS and long COVID; negative outcomes for ALS drug; donanemab
Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that explores an association between myalgic encephalomyelitis/chronic fatigue and long COVID; negative phase 3 findings on AMX0035 for ALS, and the pending approval of donanemab for Alzheimer's disease.
View all episodes
By American Academy of Neurology
4.7
1919 ratings
Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that explores an association between myalgic encephalomyelitis/chronic fatigue and long COVID; negative phase 3 findings on AMX0035 for ALS, and the pending approval of donanemab for Alzheimer's disease.
More shows like Neurology Today in 5
View all
JAMA Editors' Summary
137 Listeners
NEJM This Week
323 Listeners
JAMA Clinical Reviews
499 Listeners
Neurology® Podcast
296 Listeners
Practical Neurology Podcast
46 Listeners
JAMA Neurology Author Interviews
13 Listeners
Annals On Call Podcast
192 Listeners
JAMA Medical News
93 Listeners
The Clinical Problem Solvers
514 Listeners
Neurology Minute
136 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
368 Listeners
Neurology Exam Prep Podcast
190 Listeners
The Curious Clinicians
375 Listeners
The Lancet Neurology in conversation with
6 Listeners
Continuum Audio
83 Listeners